BCL2 and Miyoshi myopathy: Whilst initially these findings suggest that moving forward with venetoclax may not be limited to the t(11;14) subgroup when used in combination with a proteasome inhibitor and an assay measuring BCL2:MCL1 or BCL2:BCL2L1 mRNA expression ratios, the Bellini trial has cast doubt on this, with future venetoclax studies focusing on t(11;14) positive MM.